H J Burstein

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
    Lyndsay N Harris
    Dana Farber Cancer Institute
    Clin Cancer Res 13:1198-207. 2007
  2. ncbi Invasive breast cancer
    Robert W Carlson
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:246-312. 2007
  3. ncbi Novel approaches to advanced breast cancer: bevacizumab and lapatinib
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Compr Canc Netw 5:314-23. 2007
  4. ncbi Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer?
    Jennifer R Bellon
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:3916-20. 2012
  5. ncbi Ductal carcinoma in situ of the breast
    Harold J Burstein
    Division of Medical Oncology and the Department of Medicine, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1430-41. 2004
  6. ncbi Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
    Harold J Burstein
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:2889-95. 2003
  7. ncbi Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study
    Harold J Burstein
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer 110:965-72. 2007
  8. ncbi Anemia in cancer: update on studies of erythropoiesis-stimulating agents
    Harold J Burstein
    Harvard Medical School, Boston, Massachusetts, USA
    J Support Oncol 5:5-26. 2007
  9. ncbi Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 20:13-5. 2006
  10. ncbi Aromatase inhibitor-associated arthralgia syndrome
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Breast 16:223-34. 2007

Detail Information

Publications74

  1. ncbi Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
    Lyndsay N Harris
    Dana Farber Cancer Institute
    Clin Cancer Res 13:1198-207. 2007
    ....
  2. ncbi Invasive breast cancer
    Robert W Carlson
    National Comprehensive Cancer Network
    J Natl Compr Canc Netw 5:246-312. 2007
  3. ncbi Novel approaches to advanced breast cancer: bevacizumab and lapatinib
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Natl Compr Canc Netw 5:314-23. 2007
    ..This review highlights recent advances with the anti-vascular endothelial growth factor antibody, bevacizumab, and the dual kinase inhibitor, lapatinib, in the treatment of metastatic breast cancer...
  4. ncbi Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer?
    Jennifer R Bellon
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:3916-20. 2012
    ..The margins are negative, as are all 11 axillary lymph nodes. Her pathologic response to neoadjuvant treatment is judged Miller-Payne grade 4. She is referred for consideration of postmastectomy irradiation...
  5. ncbi Ductal carcinoma in situ of the breast
    Harold J Burstein
    Division of Medical Oncology and the Department of Medicine, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 350:1430-41. 2004
  6. ncbi Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm
    Harold J Burstein
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 21:2889-95. 2003
    ..We conducted a multicenter phase II study to evaluate the efficacy and safety of trastuzumab combined with vinorelbine, and to assess cardiac surveillance algorithms and tumor markers as prognostic tools...
  7. ncbi Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study
    Harold J Burstein
    Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cancer 110:965-72. 2007
    ..The trastuzumab and vinorelbine or taxane (TRAVIOTA) study was a prospective, multicenter, randomized trial that was designed to compare these regimens...
  8. ncbi Anemia in cancer: update on studies of erythropoiesis-stimulating agents
    Harold J Burstein
    Harvard Medical School, Boston, Massachusetts, USA
    J Support Oncol 5:5-26. 2007
  9. ncbi Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Oncology (Williston Park) 20:13-5. 2006
    ..This article will explore prophylactic use of both filgrastim (Neupogen) and pegfilgrastim (Neulasta) in recent clinical trials...
  10. ncbi Aromatase inhibitor-associated arthralgia syndrome
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Breast 16:223-34. 2007
    ..Treatment options for arthralgia (primarily non-steroidal anti-inflammatory drugs) are currently inadequate, but areas of active research include high-dose vitamin D and new-targeted therapies to inhibit bone loss...
  11. ncbi Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules
    Harold J Burstein
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Invest New Drugs 25:161-4. 2007
    ..Rebeccamycin analog is reasonably well tolerated on two different treatment schedules for advanced breast cancer, with modest clinical activity in this heavily pretreated population...
  12. ncbi Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons
    Harold J Burstein
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 7:158-61. 2006
    ..We believe clinicians should be aware of the potential ovarian reserve among women with treatment-related amenorrhea so as to avoid use of AI therapy in patients in whom there is uncertainty about menopausal status...
  13. ncbi Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA
    Harold J Burstein
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Expert Rev Anticancer Ther 5:581-3. 2005
  14. ncbi Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
    H J Burstein
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Ann Oncol 16:1772-7. 2005
    ..The aim of this study was to characterize the prevalence and predictors of central nervous system (CNS) metastasis among women with HER2-overexpressing metastatic breast cancer receiving trastuzumab-based therapy...
  15. ncbi Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:8340-7. 2005
    ..The role of long-acting hematopoietic growth factors in facilitating every-2-week chemotherapy and minimizing hematologic toxicity has not been established...
  16. ncbi Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 79:391-7. 2003
    ..To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer...
  17. ncbi Cognitive side-effects of adjuvant treatments
    Harold J Burstein
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Breast 16:S166-8. 2007
    ..Novel neuro-cognitive testing and imaging methods are being evaluated in breast cancer survivors to better understand cognitive side-effects of therapy...
  18. ncbi Patients with anti-HER2 responsive disease: definition and adjuvant therapies
    Harold J Burstein
    Dana Farher Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA
    Breast 20:S132-4. 2011
    ..This article will review recent information on patient and tumor selection for anti-HER2 therapy, and new data on optimal use of trastuzumab-based treatments in the adjuvant setting...
  19. ncbi Treatment of breast cancer during pregnancy
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Pharmacother 3:423-8. 2002
    ..Treatment decisions need to be tailored carefully to the individual, respecting both her clinical circumstances and her personal preferences...
  20. ncbi Adjuvant hormonal therapy for early-stage breast cancer
    Harold J Burstein
    Breast Oncology Center, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Surg Oncol Clin N Am 19:639-47. 2010
    ..Questions about the duration of adjuvant endocrine therapy, the use of biomarkers for treatment selection and prognosis, and the management of side effects of adjuvant endocrine therapy remain key areas of investigation...
  21. ncbi Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 64:496-504. 2006
    ..To evaluate the safety and feasibility of concurrent radiation therapy and paclitaxel-based adjuvant chemotherapy, given either weekly or every 3 weeks, after adjuvant doxorubicin and cyclophosphamide (AC)...
  22. ncbi Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA, USA
    J Clin Oncol 28:1301-7. 2010
    ..The efficacy and safety of neratinib were evaluated in two cohorts of patients with advanced ErbB2-positive breast cancer-those with and those without prior trastuzumab treatment-in an open-label, multicenter, phase II trial...
  23. ncbi Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1810-6. 2008
    ..This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC)...
  24. ncbi VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy
    Harold J Burstein
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 14:7871-7. 2008
    ....
  25. ncbi A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
    H J Burstein
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Ann Oncol 19:1068-74. 2008
    ..The efficacy and tolerability of the epidermal growth factor receptor/human epidermal growth factor receptor type 2 (HER2) tyrosine kinase inhibitor lapatinib in refractory metastatic breast cancer were assessed...
  26. ncbi New combinations with Herceptin in metastatic breast cancer
    E P Winer
    Dana Farber Cancer Institute, Boston, Mass 02115, USA
    Oncology 61:50-7. 2001
    ..These and other studies will identify the regimens that produce the best outcomes with the fewest possible side effects in women with HER2-positive breast cancer...
  27. ncbi The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis
    Rinaa S Punglia
    Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Cancer 106:2576-82. 2006
    ..Patients with ER+/PR+ tumors achieved optimal 10-year DFS estimates with tamoxifen followed by a crossover to AI therapy, whereas patients with ER+/PR- tumors fared best when they initiated treatment with AI...
  28. ncbi SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
    E L Mayer
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 21:2370-6. 2010
    ..Because laboratory models suggest that combining these approaches might be synergistic, we sought to evaluate the feasibility and efficacy of combining sunitinib with paclitaxel + bevacizumab (PB)...
  29. ncbi Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer
    E L Mayer
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer 224, Boston, MA 02115, USA
    Breast Cancer Res Treat 117:615-23. 2009
    ..This phase I study explored gefitinib (G) and capecitabine (C) in metastatic breast cancer (MBC)...
  30. ncbi Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis
    Rinaa S Punglia
    Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:5178-87. 2005
    ..5 years yields improved outcomes compared with either drug alone or cross-over treatment after 5 years of tamoxifen...
  31. ncbi Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
    H J Burstein
    Division of Adult Oncology and Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:2722-30. 2001
    ..CONCLUSION: Trastuzumab in combination with vinorelbine is highly active in women with HER2-overexpressing advanced breast cancer and is well tolerated...
  32. ncbi New cytotoxic agents and schedules for advanced breast cancer
    H J Burstein
    Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 28:344-58. 2001
    ..The growing availability of such biological therapies given in combination with chemotherapy may mean better survival in the future for women with advanced breast cancer...
  33. ncbi American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 28:3784-96. 2010
    ..To develop evidence-based guidelines, based on a systematic review, for endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer...
  34. ncbi Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
    M M Regan
    IBCSG Statistical Center, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
    Ann Oncol 19:1231-41. 2008
    ..PERCHE closed with inadequate accrual; TEXT accrued rapidly...
  35. ncbi Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer
    Sara M Tolaney
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 24:5330-1. 2006
  36. ncbi Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
    E M Olson
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Ann Oncol 23:93-7. 2012
    ..It is unknown whether these patients will derive further clinical benefit following treatment with trastuzumab-MCC-DM1 (T-DM1)...
  37. ncbi HER2 overexpressing metastatic breast cancer
    David R Spigel
    Breast Oncology Center, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Curr Treat Options Oncol 3:163-74. 2002
    ..While many questions remain, the treatment of HER2 overexpressing metastatic breast cancer is rapidly evolving, and represents a new approach to treatment in oncology...
  38. ncbi Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions
    Nancy U Lin
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Invest New Drugs 25:369-75. 2007
    ..Although CT-2103 had activity in this small study, neurotoxicity and hypersensitivity reactions were more frequent in this patient population than expected, and led to early termination of the trial...
  39. ncbi Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer
    Erica L Mayer
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Breast Cancer Res 9:110. 2007
    ..Ongoing studies of novel agents may lead to improved therapeutic outcomes for this high-risk population...
  40. ncbi Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
    Johanna C Bendell
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 97:2972-7. 2003
    ..Efforts to characterize other risk factors for development of CNS disease, optimal screening algorithms, and new treatment strategies may be warranted...
  41. ncbi Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis
    Rinaa S Punglia
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney St, Boston, MA 02115, USA
    J Natl Cancer Inst 100:642-8. 2008
    ....
  42. ncbi Chemotherapy for metastatic breast cancer
    Erica L Mayer
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 21:257-72. 2007
    ....
  43. ncbi American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 23:619-29. 2005
    ..To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors...
  44. ncbi Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:46-53. 2003
    ..We conducted a pilot study of preoperative trastuzumab and paclitaxel, followed by surgery and adjuvant doxorubicin and cyclophosphamide chemotherapy in earlier stage breast cancer...
  45. ncbi Lymphopenia associated with adjuvant anthracycline/ taxane regimens
    Sara M Tolaney
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Clin Breast Cancer 8:352-6. 2008
    ....
  46. ncbi Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival
    Andrea C Bafford
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Breast Cancer Res Treat 115:7-12. 2009
    ..Retrospective analyses suggest patients with stage IV breast cancer who undergo breast surgery have improved survival. We sought to determine whether surgery and other clinical and staging factors affected overall survival...
  47. ncbi The distinctive nature of HER2-positive breast cancers
    Harold J Burstein
    Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, USA
    N Engl J Med 353:1652-4. 2005
  48. ncbi Biological basis of breast cancer: an introduction
    Harold J Burstein
    Dana-Farber Cancer Institute, Boston, MA, USA
    Semin Oncol 34:S1-3. 2007
  49. ncbi Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
    Nancy U Lin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1993-9. 2008
    ..We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases...
  50. ncbi Preoperative therapy as a model for translational research in breast cancer
    Harold J Burstein
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Invest 26:217-21. 2008
  51. ncbi Gemcitabine-induced radiation recall
    Melenda D Jeter
    Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 53:394-400. 2002
    ..Treating physicians must be aware of this potential toxicity from gemcitabine and radiation and discontinue the gemcitabine if radiation recall is observed...
  52. ncbi Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment
    Gregory A Abel
    Center for Outcomes and Policy Research, Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Smith 271, Boston, MA 02115, USA
    J Clin Oncol 27:4182-7. 2009
    ..Although cancer-related direct-to-consumer advertising (CR-DTCA) is prevalent, little is known about cancer patients' experiences with this controversial medium of medical communication...
  53. ncbi Quality of non-breast cancer health maintenance among elderly breast cancer survivors
    Craig C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Center, 44 Binney St, Boston 02115, USA
    J Clin Oncol 21:1447-51. 2003
    ..To assess the quality of preventive health care, the role of health care participation, and the patient and provider characteristics associated with high-quality care for breast cancer survivors...
  54. ncbi Follow-up care of breast cancer survivors
    Ann H Partridge
    Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 30:817-25. 2003
    ..Clinicians can also provide guidance and counseling as well as psychosocial support to patients regarding medical and psychosocial decisions that may be affected by their personal history of breast cancer...
  55. ncbi American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002
    Eric P Winer
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3317-27. 2002
    ..POTENTIAL INTERVENTIONS: Anastrozole, letrozole, and exemestane...
  56. ncbi American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition
    Rowan T Chlebowski
    Health Services Research Department, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 20:3328-43. 2002
    ..To update an evidence-based technology assessment of chemoprevention strategies for breast cancer risk reduction. POTENTIAL INTERVENTIONS: Tamoxifen, raloxifene, aromatase inhibition, and fenretinide...
  57. ncbi Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer
    Erica L Mayer
    J Clin Oncol 26:1198-200. 2008
  58. ncbi HER2 or not HER2: that is the question
    Harold J Burstein
    J Clin Oncol 23:3656-9. 2005
  59. ncbi American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting
    Eric P Winer
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 21:2597-9. 2003
  60. ncbi American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    J Clin Oncol 23:7703-20. 2005
    ..To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer...
  61. ncbi NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
    Robert W Carlson
    Stanford Hospital and Clinics, Stanford University, Stanford, CA, USA
    J Natl Compr Canc Netw 4:S1-26. 2006
    ..This supplement summarizes the background data and ensuing discussion from the Adjuvant Task Force meeting...
  62. ncbi Breast cancer
    Robert W Carlson
    Stanford Hospital and Clinics, USA
    J Natl Compr Canc Netw 3:238-89. 2005
  63. ncbi HER2 testing in breast cancer: NCCN Task Force report and recommendations
    Robert W Carlson
    Stanford Hospital and Clinics
    J Natl Compr Canc Netw 4:S1-22; quiz S23-4. 2006
    ..8 to 2.2 or average number of HER2 gene copies/cell in the range of greater than 4 to less than 6 are considered to be borderline, and strategies to assign the HER2 status of such samples are proposed...
  64. ncbi American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays
    Deborah Schrag
    American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, Alexandria, VA 22314, USA
    J Clin Oncol 22:3631-8. 2004
    ..Because the in vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority...
  65. ncbi Trastuzumab regimens for HER2-overexpressing metastatic breast cancer
    David R Spigel
    Sarah Cannon Cancer Center, Nashville, TN, USA
    Clin Breast Cancer 4:329-37; discussion 338-9. 2003
    ..This review briefly outlines the evolving role of trastuzumab in the treatment of HER2-overexpressing metastatic breast cancer...
  66. ncbi Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer
    Harold J Burstein
    N Engl J Med 349:1857-9. 2003
  67. ncbi Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors
    Harold J Burstein
    J Clin Oncol 25:3797-9. 2007
  68. ncbi The role of angiogenesis inhibition in the treatment of breast cancer
    George W Sledge
    Indiana University Cancer Center, Indianapolis, Ind, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ..Combination therapy consisting of antiangiogenic agents with chemotherapy, hormone therapy, or other agents is also being evaluated in hopes of improving treatment options for these patients...
  69. ncbi Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease
    Julie R Gralow
    Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3 200, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:814-9. 2008
    ..To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer...
  70. ncbi Standards for follow-up care of patents with breast cancer
    Jeffery Peppercorn
    Breast 14:500-8. 2005
  71. ncbi NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer
    Donald A Podoloff
    J Natl Compr Canc Netw 5:S1-S22; quiz S23-2. 2007
    ..This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology...
  72. ncbi Do patients participating in clinical trials want to know study results?
    Ann H Partridge
    J Natl Cancer Inst 95:491-2. 2003
  73. ncbi NCCN Task Force Report: breast cancer in the older woman
    Robert W Carlson
    J Natl Compr Canc Netw 6:S1-S25; quiz S26-S27. 2008
    ....
  74. ncbi Molecular origins of cancer
    Harold J Burstein
    N Engl J Med 358:527. 2008